Envestnet Portfolio Solutions Inc. Has $1.14 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,169 shares of the biopharmaceutical company’s stock after purchasing an additional 398 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,139,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of REGN. Brighton Jones LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 41.8% during the first quarter. GAMMA Investing LLC now owns 1,286 shares of the biopharmaceutical company’s stock worth $816,000 after purchasing an additional 379 shares during the period. Ritholtz Wealth Management raised its stake in Regeneron Pharmaceuticals by 7.8% during the first quarter. Ritholtz Wealth Management now owns 486 shares of the biopharmaceutical company’s stock worth $308,000 after buying an additional 35 shares during the last quarter. Sowell Financial Services LLC bought a new position in Regeneron Pharmaceuticals during the first quarter worth $353,000. Finally, Kingswood Wealth Advisors LLC boosted its position in Regeneron Pharmaceuticals by 1.8% during the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company’s stock valued at $681,000 after acquiring an additional 19 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.6%

REGN opened at $578.05 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,002.69. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a market cap of $61.27 billion, a P/E ratio of 14.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. The company has a fifty day moving average price of $574.64 and a two-hundred day moving average price of $562.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period in the previous year, the firm posted $11.56 earnings per share. The business’s revenue was up 3.6% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Canaccord Genuity Group reiterated a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 14th. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Finally, Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a report on Monday, August 4th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $817.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.